Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q4 2018 · 10-K
Revenue$89.69M$89.69M+48.5% vs Q4 2017 Net Income$1.87M$1.87M+27.2% vs Q4 2017 EPS Diluted$0.04$0.04+100.0% vs Q4 2017 Gross Profit$34,689,000+69.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived$9,517,000−2.5% Free Cash Flowderived-$65,000N/M Margins · derivedGross margin38.7%+4.8 pt vs Q4 2017
Operating margin1.7%+4.9 pt vs Q4 2017
Net margin2.1%−0.3 pt vs Q4 2017
ended Dec 31, 2018 · filed Mar 15, 2019 · 74 d after period end